{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:43:16Z","timestamp":1785523396351,"version":"3.56.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01538-1","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:21:52Z","timestamp":1785169312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Scientific synergy between prophylactic and therapeutic HIV vaccines\u2014prevention and cure"],"prefix":"10.1038","volume":"11","author":[{"suffix":"Jr","given":"Milton","family":"Maciel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine J.","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Calder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Malaspina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurine D.","family":"Miner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart Z.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6631-7615","authenticated-orcid":false,"given":"M. Patricia","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"1538_CR1","volume":"4","author":"E Brazier","year":"2026","unstructured":"Brazier, E. et al. Impact of US government funding freezes on the HIV response: findings from a rapid survey in 32 countries. Health Aff. Sch. 4, qxag020 (2026).","journal-title":"Health Aff. Sch."},{"key":"1538_CR2","unstructured":"Prevention, C.f.D.C.a. Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through March 2025. https:\/\/www.cdc.gov\/hiv-data\/initiatives\/ (2025)."},{"key":"1538_CR3","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","volume":"391","author":"LG Bekker","year":"2024","unstructured":"Bekker, L. G. et al. Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N. Engl. J. Med. 391, 1179\u20131192 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1538_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz, R. J. et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N. Engl. J. Med. 385, 595\u2013608 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1538_CR5","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2352-3018(24)00098-5","volume":"11","author":"C Beyrer","year":"2024","unstructured":"Beyrer, C. et al. Is HIV epidemic control by 2030 realistic? Lancet HIV 11, e489\u2013e494 (2024).","journal-title":"Lancet HIV"},{"key":"1538_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25463","volume":"23","author":"J Velloza","year":"2020","unstructured":"Velloza, J. et al. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. J. Int. AIDS Soc. 23, e25463 (2020).","journal-title":"J. Int. AIDS Soc."},{"key":"1538_CR7","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","volume":"384","author":"L Corey","year":"2021","unstructured":"Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003\u20131014 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1538_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43384-y","volume":"14","author":"DB Reeves","year":"2023","unstructured":"Reeves, D. B. et al. High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the antibody mediated prevention trials. Nat. Commun. 14, 8299 (2023).","journal-title":"Nat. Commun."},{"key":"1538_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25831","volume":"24","author":"WB Williams","year":"2021","unstructured":"Williams, W. B., Wiehe, K., Saunders, K. O. & Haynes, B. F. Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies. J. Int. AIDS Soc. 24, e25831 (2021).","journal-title":"J. Int. AIDS Soc."},{"key":"1538_CR10","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1016\/S2352-3018(25)00373-X","volume":"13","author":"T Ndung\u2019u","year":"2026","unstructured":"Ndung\u2019u, T. et al. Recommendations from the 2nd consensus workshop on analytical treatment interruption in HIV research trials. Lancet HIV 13, e271\u2013e281 (2026).","journal-title":"Lancet HIV"},{"key":"1538_CR11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1084\/jem.20151960","volume":"213","author":"R Rappuoli","year":"2016","unstructured":"Rappuoli, R., Bottomley, M. J., D\u2019Oro, U., Finco, O. & De Gregorio, E. Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. J. Exp. Med. 213, 469\u2013481 (2016).","journal-title":"J. Exp. Med."},{"key":"1538_CR12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.2174\/011570162X358302250206074255","volume":"23","author":"L Stamatatos","year":"2025","unstructured":"Stamatatos, L. The germline targeting vaccine concept: overview and updates from HIV pre-clinical and clinical trials. Curr. HIV Res. 23, 380\u2013390 (2025).","journal-title":"Curr. HIV Res."},{"key":"1538_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1126\/science.aac5894","volume":"349","author":"JG Jardine","year":"2015","unstructured":"Jardine, J. G. et al. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349, 156\u2013161 (2015).","journal-title":"Science"},{"key":"1538_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf3309","volume":"15","author":"KW Cohen","year":"2023","unstructured":"Cohen, K. W. et al. A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses. Sci. Transl. Med. 15, eadf3309 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1538_CR15","doi-asserted-by":"publisher","first-page":"6688","DOI":"10.1016\/j.cell.2025.10.023","volume":"188","author":"WB Williams","year":"2025","unstructured":"Williams, W. B. et al. Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans. Cell 188, 6688\u20136689 (2025).","journal-title":"Cell"},{"key":"1538_CR16","doi-asserted-by":"publisher","first-page":"aag0851","DOI":"10.1126\/sciimmunol.aag0851","volume":"1","author":"MA Moody","year":"2016","unstructured":"Moody, M. A. et al. Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies. Sci. Immunol. 1, aag0851 (2016).","journal-title":"Sci. Immunol."},{"key":"1538_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cell.2018.08.064","volume":"175","author":"T Bradley","year":"2018","unstructured":"Bradley, T. et al. RAB11FIP5 expression and altered natural killer cell function are associated with induction of HIV broadly neutralizing antibody responses. Cell 175, 387\u2013399.e317 (2018).","journal-title":"Cell"},{"key":"1538_CR18","doi-asserted-by":"publisher","unstructured":"Garcia, M. A. et al. Inhibitory potential of autologous neutralizing antibodies sets quantitative limits on the rebound-competent HIV-1 reservoir. Biorxiv : the Preprint Server for Biology. 2025 Dec:2025.12.07.692769. https:\/\/doi.org\/10.64898\/2025.12.07.692769.","DOI":"10.64898\/2025.12.07.692769"},{"key":"1538_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","volume":"566","author":"KM Bruner","year":"2019","unstructured":"Bruner, K. M. et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature 566, 120\u2013125 (2019).","journal-title":"Nature"},{"key":"1538_CR20","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nm1777","volume":"14","author":"L Shen","year":"2008","unstructured":"Shen, L. et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 14, 762\u2013766 (2008).","journal-title":"Nat. Med."},{"key":"1538_CR21","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1038\/s41591-022-01953-6","volume":"28","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. Nat. Med. 28, 1924\u20131932 (2022).","journal-title":"Nat. Med."},{"key":"1538_CR22","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/S2352-3018(23)00293-X","volume":"11","author":"JJ Eron","year":"2024","unstructured":"Eron, J. J. et al. Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study. Lancet HIV 11, e146\u2013e155 (2024).","journal-title":"Lancet HIV"},{"key":"1538_CR23","first-page":"187","volume":"650","author":"MJ Peluso","year":"2025","unstructured":"Peluso, M. J. et al. Combination immunotherapy induces post-intervention control of HIV. Res. Sq. 650, 187\u2013195 (2025).","journal-title":"Res. Sq."},{"key":"1538_CR24","doi-asserted-by":"publisher","unstructured":"Fumagalli, M. J. et al. Enhanced HIV-1 control after antibody therapy is associated with autologous antibodies and reservoir clearance in the RIO trial. Preprint at https:\/\/doi.org\/10.1101\/2025.11.03.25339415 (2025).","DOI":"10.1101\/2025.11.03.25339415"},{"key":"1538_CR25","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/s41586-025-09330-2","volume":"645","author":"A Ardeshir","year":"2025","unstructured":"Ardeshir, A. et al. Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life. Nature 645, 1020\u20131028 (2025).","journal-title":"Nature"},{"key":"1538_CR26","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1016\/S1473-3099(23)00481-4","volume":"24","author":"A Trkola","year":"2024","unstructured":"Trkola, A. & Moore, P. L. Vaccinating people living with HIV: a fast track to preventive and therapeutic HIV vaccines. Lancet Infect. Dis. 24, e252\u2013e255 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1538_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/science.adv5572","volume":"389","author":"TG Caniels","year":"2025","unstructured":"Caniels, T. G. et al. Precise targeting of HIV broadly neutralizing antibody precursors in humans. Science 389, eadv5572 (2025).","journal-title":"Science"},{"key":"1538_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29511-1","volume":"13","author":"LM Molinos-Albert","year":"2022","unstructured":"Molinos-Albert, L. M. et al. Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers. Nat. Commun. 13, 1944 (2022).","journal-title":"Nat. Commun."},{"key":"1538_CR29","doi-asserted-by":"publisher","first-page":"e2218960120","DOI":"10.1073\/pnas.2218960120","volume":"120","author":"B Etemad","year":"2023","unstructured":"Etemad, B. et al. HIV post-treatment controllers have distinct immunological and virological features. Proc. Natl. Acad. Sci. USA. 120, e2218960120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1538_CR30","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1038\/s41467-026-69720-6","volume":"17","author":"C Charre","year":"2026","unstructured":"Charre, C. et al. Post-treatment SIV control is associated with specific features of viral persistence before and after treatment interruption. Nat. Commun. 17, 3290\u20133310 (2026).","journal-title":"Nat. Commun."},{"key":"1538_CR31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41586-025-09932-w","volume":"650","author":"Z Kiani","year":"2026","unstructured":"Kiani, Z. et al. CD8(+) T cell stemness precedes post-intervention control of HIV viraemia. Nature 650, 196\u2013204 (2026).","journal-title":"Nature"},{"key":"1538_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57284-w","volume":"16","author":"L Bailon","year":"2025","unstructured":"Bailon, L. et al. Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial. Nat. Commun. 16, 2146 (2025).","journal-title":"Nat. Commun."},{"key":"1538_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/COH.0000000000000824","volume":"18","author":"GM Borgo","year":"2023","unstructured":"Borgo, G. M. & Rutishauser, R. L. Generating and measuring effective vaccine-elicited HIV-specific CD8 + T cell responses. Curr. Opin. HIV AIDS 18, 331\u2013341 (2023).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"1538_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41586-025-09929-5","volume":"650","author":"MJ Peluso","year":"2026","unstructured":"Peluso, M. J. et al. Correlates of HIV-1 control after combination immunotherapy. Nature 650, 187\u2013195 (2026).","journal-title":"Nature"},{"key":"1538_CR35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev-immunol-082724-125809","volume":"44","author":"AO Papadopoulos","year":"2026","unstructured":"Papadopoulos, A. O., Moodley, M., Mendoza, C. A. & Ndhlovu, Z. M. CD8+ T cell immunity in HIV cure and prevention: linking stemness, spatial niches, and emerging therapeutic strategies. Annu. Rev. Immunol. 44, 95\u2013120 (2026).","journal-title":"Annu. Rev. Immunol."},{"key":"1538_CR36","first-page":"E3413","volume":"113","author":"H Li","year":"2016","unstructured":"Li, H. et al. Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc. Natl. Acad. Sci. USA. 113, E3413\u2013E3422 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1538_CR37","doi-asserted-by":"crossref","unstructured":"Roark, R.S. et al. Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Science 371, eabd2638 (2021).","DOI":"10.1126\/science.abd2638"},{"key":"1538_CR38","volume":"11","author":"R Habib","year":"2026","unstructured":"Habib, R. et al. Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody development. Sci. Immunol. 11, eadz3933 (2026).","journal-title":"Sci. Immunol."},{"key":"1538_CR39","doi-asserted-by":"publisher","first-page":"eaec6396","DOI":"10.1126\/science.aec6396","volume":"392","author":"AN Skelly","year":"2026","unstructured":"Skelly, A.N. et al. Induction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design. Science 392, eaec6396 (2026).","journal-title":"Science"},{"key":"1538_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53120-9","volume":"15","author":"R Henderson","year":"2024","unstructured":"Henderson, R. et al. Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies. Nat. Commun. 15, 9503 (2024).","journal-title":"Nat. Commun."},{"key":"1538_CR41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","unstructured":"Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409, 131\u2013146 (2014).","journal-title":"J. Immunol. Methods"},{"key":"1538_CR42","doi-asserted-by":"publisher","first-page":"103056","DOI":"10.1016\/j.xpro.2024.103056","volume":"5","author":"M Schwarzmuller","year":"2024","unstructured":"Schwarzmuller, M. & Trkola, A. ART-DEX: A novel strategy to monitor broadly neutralizing antibody activity during antiretroviral therapy of HIV-1. STAR Protoc. 5, 103056 (2024).","journal-title":"STAR Protoc."},{"key":"1538_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01168-z","volume":"10","author":"M Maciel Jr.","year":"2025","unstructured":"Maciel, M. Jr. et al. Optimizing human B cell repertoire analyses to interpret clinical data and design sequential HIV vaccines. NPJ Vaccines 10, 157 (2025).","journal-title":"NPJ Vaccines"},{"key":"1538_CR44","doi-asserted-by":"publisher","unstructured":"Erdmann, N. et al. An HIV-1 gp41 peptide-liposome vaccine elicits neutralizing epitope-targeted antibody responses in healthy individuals. Preprint at https:\/\/doi.org\/10.1101\/2024.03.15.24304305 (2025).","DOI":"10.1101\/2024.03.15.24304305"},{"key":"1538_CR45","doi-asserted-by":"publisher","unstructured":"Walsh, S. et al. Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300). Preprint at https:\/\/doi.org\/10.64898\/2026.03.31.26349761 (2026).","DOI":"10.64898\/2026.03.31.26349761"},{"key":"1538_CR46","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1038\/s41591-022-02023-7","volume":"28","author":"JD Gunst","year":"2022","unstructured":"Gunst, J. D. et al. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b\/2a, randomized trial. Nat. Med. 28, 2424\u20132435 (2022).","journal-title":"Nat. Med."},{"key":"1538_CR47","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41591-020-0774-y","volume":"26","author":"DJ Colby","year":"2020","unstructured":"Colby, D. J. et al. Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. Nat. Med. 26, 498\u2013501 (2020).","journal-title":"Nat. Med."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01538-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01538-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01538-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:25:34Z","timestamp":1785518734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01538-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1538"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01538-1","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"24 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"154"}}